INSP — Inspire Medical Systems, Inc.

Is INSP overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Devices

Oversold As of November 17, 2026

Inspire Medical Systems, Inc. (INSP) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Devices) last closed at $59.12. The rating moved from Neutral to Oversold on November 12, 2026.

See all oversold Healthcare stocks →

AI analysis

Inspire Medical Systems, Inc. (INSP) benefits from a differentiated implanted therapy for obstructive sleep apnea with established clinical evidence and expanding commercial penetration. Revenue and margin trajectories are supported by increasing procedure volumes, recurring implant-related revenue, and international expansion opportunities. Key near-term catalysts include broader payer adoption, expansion of referral networks, and potential label/indication additions. Principal risks are reimbursement shifts, competitive pressures from other sleep-apnea solutions, execution challenges in scaling procedures and supply chain disruptions, and the potential for adverse device or safety events. Current social and market commentary in the four‑hour window was muted, suggesting limited short‑term sentiment-driven volatility; monetary policy focus may keep larger market moves in check. Overall, the outlook includes a path to continued top-line growth if commercialization execution and favorable payer dynamics persist, while downside scenarios hinge on reimbursement or safety setbacks.

Key factors

  • Proprietary hypoglossal nerve stimulation therapy with differentiated clinical outcomes versus long‑term CPAP nonadherence; strong clinical evidence supports adoption
  • Growing commercial footprint in the U.S. with improving procedure volumes and expanding physician base driving recurring implant-related revenue
  • Favorable reimbursement environment for obstructive sleep apnea devices and potential upside from Medicare/MA coverage improvements
  • Multiple near‑term growth levers: international rollouts, label or indication expansions, and expanded referral pathways from ENT and sleep specialists
  • Capital allocation focused on commercialization and targeted R&D rather than heavy acquisition risk, supporting margin expansion as volumes scale
  • Limited social/media volatility in the most recent window and an overall measured market tone reduce short‑term volatility risk

Risks

  • Reimbursement pressure or adverse changes in Medicare/Medicare Advantage policies that could slow procedure uptake or reduce pricing
  • Competition from next‑generation implantable devices, competitive non‑invasive therapies, or incremental CPAP improvements
  • Operational execution risk: slower-than-expected commercialization outside core markets, supply chain interruptions, or constraints on procedure access
  • Clinical or device safety issues/recalls that could materially impact adoption and create negative perception among physicians and payors
  • Valuation sensitivity: if revenue growth misses expectations, the stock could reprice given the growth‑oriented investor base
  • Regulatory risk for new indications or international approvals that could delay market expansion

See today's live rating, score and targets

Members see the live hourly rating for INSP — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.